van Dort, M. J. http://orcid.org/0000-0002-0927-4206
Driessen, J. H. M.
Geusens, P.
Romme, E. A. P. M.
Smeenk, F. W. J. M.
Rahel, B. M.
Eisman, J. A.
Wouters, E. F. M.
van den Bergh, J. P. W.
Funding for this research was provided by:
Stichting De Weijerhorst
Article History
Received: 2 November 2018
Accepted: 30 October 2019
First Online: 25 November 2019
Compliance with ethical standards
:
: This research was performed independently from funders.
: Prof. Geusens reports grants, speaker fees and advisory board from Amgen, grants from Pfizer, grants from MSD, grants from UCB, grants from Abbott, grants and speaker fees from Lilly, grants from BMS, grants from Novartis, grants from Roche, and grants from Will Pharma, outside the submitted work. Prof. Eisman reports grants and honoraria from Eli Lilly, Amgen and Merck, outside the submitted work. Prof. Wouters reports board membership at Boehringer, grants and speaker fees from AstraZeneca, grants and speaker fees from GSK, speaker fees from Novartis, and speaker fees from Chiesi, outside the submitted work. Prof. van den Bergh reports grants from Eli Lilly, grants from Will Pharma, and grants from Amgen, outside the submitted work. The rest of the authors have nothing to disclose.